Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Arbutus Biopharma CorpABUS · Entity 4953 | Director | May 23, 2024 | May 24, 2024 |
| CytomX Therapeutics, Inc.CTMX · Entity 5124 | Director | June 17, 2026 | June 22, 2026 |
| SANGAMO THERAPEUTICS, INCSGMO · Entity 7038 | Director | June 12, 2025 | June 16, 2025 |
| Vera Therapeutics, Inc.VERA · Entity 4358 | Director | May 21, 2026 | May 26, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Arbutus Biopharma Corp
Report date May 23, 2024 · Filed May 24, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.28 · Expires 2034-05-23 | Direct | 67,000 |
Reported balance
After 2024-05-23 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-05-23 · Grant · Acquired 67,000 · Balance 67,000 F1: Reflects the closing price of the Company's common shares on the Nasdaq Stock Market on the date of the grant. F2: The option is fully vested and exercisable as of the date of the grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects the closing price of the Company's common shares on the Nasdaq Stock Market on the date of the grant.
F2: The option is fully vested and exercisable as of the date of the grant.
CytomX Therapeutics, Inc.
Report date June 17, 2026 · Filed June 22, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.96 · Expires 2036-06-16 | Direct | 59,000 |
Reported balance
After 2026-06-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-17 · Grant · Acquired 59,000 · Balance 59,000 F1: 100% of the shares subject to the option shall vest in full on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2027 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: 100% of the shares subject to the option shall vest in full on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2027 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date.
SANGAMO THERAPEUTICS, INC
Report date June 12, 2025 · Filed June 16, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 99,600 |
Reported balance
After 2025-06-12 transaction · row 1
1 source rowRow 1 · 2025-06-12 · Grant · Acquired 25,000 · Balance 99,600 F1: Represents shares of common stock issuable upon settlement of a restricted stock unit ("RSU") grant that will fully vest on the earlier of (a) June 12, 2026 or (b) the day prior to the 2026 annual meeting of stockholders, subject to the Reporting Person's Continuous Service (as defined in the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP")) through such date and subject to acceleration as provided in the 2018 EIP. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.50 · Expires 2035-06-11 | Direct | 50,000 |
Reported balance
After 2025-06-12 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-06-12 · Grant · Acquired 50,000 · Balance 50,000 F2: The option is immediately exercisable in full, but any unvested shares that are purchased under the option are subject to certain repurchase rights by the Issuer upon cessation of the Reporting Person's Continuous Service (as defined in the 2018 EIP). The shares subject to the option will vest in 12 successive equal monthly installments following the grant date, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of common stock issuable upon settlement of a restricted stock unit ("RSU") grant that will fully vest on the earlier of (a) June 12, 2026 or (b) the day prior to the 2026 annual meeting of stockholders, subject to the Reporting Person's Continuous Service (as defined in the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP")) through such date and subject to acceleration as provided in the 2018 EIP.
F2: The option is immediately exercisable in full, but any unvested shares that are purchased under the option are subject to certain repurchase rights by the Issuer upon cessation of the Reporting Person's Continuous Service (as defined in the 2018 EIP). The shares subject to the option will vest in 12 successive equal monthly installments following the grant date, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP.
Vera Therapeutics, Inc.
Report date May 21, 2026 · Filed May 26, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $34.35 · Expires 2036-05-20 | Direct | 17,084 |
Reported balance
After 2026-05-21 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-21 · Grant · Acquired 17,084 · Balance 17,084 F1: The shares subject to the option will vest in full on the earlier of the first anniversary of the grant date or the date of the Company's 2027 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date. Notwithstanding the foregoing, the shares will vest in full upon a change in control, subject to the Reporting Person's continuous service through the date of such change in control. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option will vest in full on the earlier of the first anniversary of the grant date or the date of the Company's 2027 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date. Notwithstanding the foregoing, the shares will vest in full upon a change in control, subject to the Reporting Person's continuous service through the date of such change in control.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
GILEAD SCIENCES, INC.
Report date February 15, 2018 · Filed February 23, 2018
Section 16 reporting ended · disclosed 2018-02-23. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 5,393 |
Ending reported balance
After 2018-02-21 transaction · row 5
5 source rows · reconciled sequenceRow 1 · 2018-02-15 · Grant · Acquired 221 · Balance 2,936 F1: Shares were acquired under the Gilead Sciences, Inc. Employee Stock Purchase Plan. Row 2 · 2018-02-21 · Grant · Acquired 4,846 · Balance 7,782 F2: Represents shares of the Issuer's common stock subject to specific tranches of the performance share awards made to the Reporting Person on February 1, 2016, and February 2, 2017. Such tranches of shares were subject to both performance-vesting and service-vesting requirements. The performance vesting requirement was satisfied on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of the Issuer's Board of Directors. However, the shares will not be issued to the Reporting Person until such individual satisfies the applicable service-vesting requirements by continuing in the Issuer's employ through December 31, 2018 and December 31, 2019, respectively. Row 3 · 2018-02-21 · Grant · Acquired 1,581 · Balance 9,363 F3: Represents shares of the Issuer's common stock subject to specific tranches of the performance share award made to the Reporting Person on February 1, 2015. Such tranches of shares were subject to performance-vesting and service-vesting requirements and became issuable on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of the Issuer's Board of Directors. Row 4 · 2018-02-21 · Tax withholding · Disposed 1,647 · Balance 7,716 Row 5 · 2018-02-21 · Gift · Disposed 2,323 · Balance 5,393 F4: Shares gifted to family trust. |
| Common StockSEC Table I · non-derivative | IndirectBy Trust | 132,083 |
Reported balance
After 2018-02-21 transaction · row 6
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 6 · 2018-02-21 · Gift · Acquired 2,323 · Balance 132,083 F4: Shares gifted to family trust. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares were acquired under the Gilead Sciences, Inc. Employee Stock Purchase Plan.
F2: Represents shares of the Issuer's common stock subject to specific tranches of the performance share awards made to the Reporting Person on February 1, 2016, and February 2, 2017. Such tranches of shares were subject to both performance-vesting and service-vesting requirements. The performance vesting requirement was satisfied on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of the Issuer's Board of Directors. However, the shares will not be issued to the Reporting Person until such individual satisfies the applicable service-vesting requirements by continuing in the Issuer's employ through December 31, 2018 and December 31, 2019, respectively.
F3: Represents shares of the Issuer's common stock subject to specific tranches of the performance share award made to the Reporting Person on February 1, 2015. Such tranches of shares were subject to performance-vesting and service-vesting requirements and became issuable on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of the Issuer's Board of Directors.
F4: Shares gifted to family trust.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 17, 2026 Filed Jun 22, 2026 20:49 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | GrantStock Option (Right to Buy) · Derivative | 59,000 | $0.00 Strike: $2.96 | $0.00 |
DisclosureSEC source: 0001610717-26-000277 · form4.xml · derivative · entry 1 Meyers James R · CIK 0001387521 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 59,000 Underlying: Common Stock · 59,000 shares Expires 2036-06-16 F1 · derivative.exercise_date: 100% of the shares subject to the option shall vest in full on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2027 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date. Read SEC document |
| May 21, 2026 Filed May 26, 2026 20:19 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | GrantStock Option (right to buy) · Derivative | 17,084 | $0.00 Strike: $34.35 | $0.00 |
DisclosureSEC source: 0001387521-26-000002 · form4-05262026_080541.xml · derivative · entry 1 Meyers James R · CIK 0001387521 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,084 Underlying: Class A Common Stock · 17,084 shares Expires 2036-05-20 F1 · derivative.exercise_date: The shares subject to the option will vest in full on the earlier of the first anniversary of the grant date or the date of the Company's 2027 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date. Notwithstanding the foregoing, the shares will vest in full upon a change in control, subject to the Reporting Person's continuous service through the date of such change in control. Read SEC document |
| November 25, 2025 Filed Nov 26, 2025 21:37 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $29.43 | $0.00 |
DisclosureSEC source: 0001193125-25-300677 · ownership.xml · derivative · entry 1 Meyers James R · CIK 0001387521 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Class A Common Stock · 25,000 shares Expires 2035-11-24 F1 · derivative.exercise_date: The shares subject to the stock option will vest monthly over a three-year period subject to the Reporting Person's continuous service on each vesting date. Notwithstanding the foregoing, the shares will vest in full upon a change in control, subject to the Reporting Person's continuous service through the date of such change in control. Read SEC document |
| June 12, 2025 Filed Jun 16, 2025 20:05 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $0.50 | $0.00 |
DisclosureSEC source: 0001415889-25-017372 · form4-06162025_040611.xml · derivative · entry 2 Meyers James R · CIK 0001387521 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2035-06-11 F2 · derivative.exercise_date: The option is immediately exercisable in full, but any unvested shares that are purchased under the option are subject to certain repurchase rights by the Issuer upon cessation of the Reporting Person's Continuous Service (as defined in the 2018 EIP). The shares subject to the option will vest in 12 successive equal monthly installments following the grant date, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP. Read SEC document |
| June 12, 2025 Filed Jun 16, 2025 20:05 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | GrantCommon Stock | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-017372 · form4-06162025_040611.xml · nonDerivative · entry 1 Meyers James R · CIK 0001387521 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 99,600 F1 · shares: Represents shares of common stock issuable upon settlement of a restricted stock unit ("RSU") grant that will fully vest on the earlier of (a) June 12, 2026 or (b) the day prior to the 2026 annual meeting of stockholders, subject to the Reporting Person's Continuous Service (as defined in the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP")) through such date and subject to acceleration as provided in the 2018 EIP. Read SEC document |
| June 11, 2025 Filed Jun 13, 2025 20:17 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | GrantStock Option (Right to Buy) · Derivative | 38,000 | $0.00 Strike: $2.82 | $0.00 |
DisclosureSEC source: 0001610717-25-000212 · form4.xml · derivative · entry 1 Meyers James R · CIK 0001387521 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,000 Underlying: Common Stock · 38,000 shares Expires 2035-06-10 F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2026 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date. Read SEC document |
| June 04, 2024 Filed Jun 6, 2024 20:25 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $0.57 | $0.00 |
DisclosureSEC source: 0001415889-24-015759 · form4-06062024_080624.xml · derivative · entry 2 Meyers James R · CIK 0001387521 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2034-06-03 F2 · derivative.exercise_date: The option is immediately exercisable in full, but any unvested shares that are purchased under the option are subject to certain repurchase rights by the Issuer upon cessation of the Reporting Person's Continuous Service (as defined in the 2018 EIP). The shares subject to the option will vest in 12 successive equal monthly installments following the grant date, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP. Read SEC document |
| June 04, 2024 Filed Jun 6, 2024 20:25 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | GrantCommon Stock | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-015759 · form4-06062024_080624.xml · nonDerivative · entry 1 Meyers James R · CIK 0001387521 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 74,600 F1 · shares: Represents shares of common stock issuable upon settlement of a restricted stock unit ("RSU") grant that will fully vest on the earlier of (a) June 4, 2025 or (b) the day prior to the 2025 annual meeting of stockholders, subject to the Reporting Person's Continuous Service (as defined in the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP")) through such date and subject to acceleration as provided in the 2018 EIP. Read SEC document |
| May 23, 2024 Filed May 24, 2024 20:12 UTC | Arbutus Biopharma Corp ABUS · Entity 4953 | GrantStock Option (Right to Buy) · Derivative | 67,000 | $0.00 Strike: $3.28 | $0.00 |
DisclosureSEC source: 0001447028-24-000053 · wk-form4_1716581555.xml · derivative · entry 1 Meyers James R · CIK 0001387521 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 67,000 Underlying: Common Shares · 67,000 shares Expires 2034-05-23 F1 · derivative.exercise_price: Reflects the closing price of the Company's common shares on the Nasdaq Stock Market on the date of the grant. F2 · derivative.exercise_date: The option is fully vested and exercisable as of the date of the grant. Read SEC document |
| May 15, 2024 Filed May 17, 2024 21:34 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | GrantStock Option (Right to Buy) · Derivative | 38,000 | $0.00 Strike: $1.96 | $0.00 |
DisclosureSEC source: 0001610717-24-000245 · form4.xml · derivative · entry 1 Meyers James R · CIK 0001387521 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,000 Underlying: Common Stock · 38,000 shares Expires 2034-05-14 F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2025 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date. Read SEC document |
| June 14, 2023 Filed Jun 16, 2023 21:54 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $1.57 | $0.00 |
DisclosureSEC source: 0001610717-23-000183 · form4.xml · derivative · entry 1 Meyers James R · CIK 0001387521 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2033-06-13 F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2024 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date. Read SEC document |
| June 01, 2023 Filed Jun 5, 2023 20:50 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | GrantStock Option (Right to Buy) · Derivative | 27,750 | $0.00 Strike: $1.11 | $0.00 |
DisclosureSEC source: 0001209191-23-034401 · doc4.xml · derivative · entry 2 Meyers James R · CIK 0001387521 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,750 Underlying: Common Stock · 27,750 shares Expires 2033-05-31 F2 · derivative.exercise_date: The option is immediately exercisable in full, but any unvested shares that are purchased under the option are subject to certain repurchase rights by the Issuer upon cessation of the Reporting Person's Continuous Service (as defined in the 2018 EIP). The shares subject to the option will vest in 12 successive equal monthly installments following the grant date, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP. Read SEC document |
| June 01, 2023 Filed Jun 5, 2023 20:50 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | GrantCommon Stock | 13,900 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-034401 · doc4.xml · nonDerivative · entry 1 Meyers James R · CIK 0001387521 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,600 F1 · shares: Represents shares of common stock issuable upon settlement of a restricted stock unit grant that will fully vest on the earlier of (a) June 1, 2024 or (b) the day prior to the 2024 annual meeting of stockholders, subject to the Reporting Person's Continuous Service (as defined in the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP")) through such date and subject to acceleration as provided in the 2018 EIP. Read SEC document |
| May 24, 2023 Filed May 26, 2023 20:06 UTC | Arbutus Biopharma Corp ABUS · Entity 4953 | GrantStock Option (Right to Buy) · Derivative | 55,000 | $0.00 Strike: $2.56 | $0.00 |
DisclosureSEC source: 0001447028-23-000040 · wk-form4_1685131561.xml · derivative · entry 1 Meyers James R · CIK 0001387521 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,000 Underlying: Common Shares · 55,000 shares Expires 2033-05-24 F1 · derivative.exercise_price: Reflects the closing price of the Company's common shares on the Nasdaq Stock Market on May 24, 2023, the date of the grant. F2 · derivative.exercise_date: The option is fully vested and exercisable as of the date of the grant. Read SEC document |
| June 15, 2022 Filed Jun 17, 2022 20:06 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $1.72 | $0.00 |
DisclosureSEC source: 0001567619-22-013073 · doc1.xml · derivative · entry 1 Meyers James R · CIK 0001387521 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2032-06-14 F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2023 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date. Read SEC document |
| May 25, 2022 Filed May 26, 2022 20:16 UTC | Arbutus Biopharma Corp ABUS · Entity 4953 | GrantStock Option (Right to Buy) · Derivative | 41,000 | $0.00 Strike: $2.25 | $0.00 |
DisclosureSEC source: 0001447028-22-000036 · wf-form4_165359615932033.xml · derivative · entry 1 Meyers James R · CIK 0001387521 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,000 Underlying: Common Shares · 41,000 shares Expires 2032-05-25 F1 · derivative.exercise_price: Reflects the closing price of the Company's common shares on the Nasdaq Stock Market on May 25, 2022, the date of the grant. F2 · derivative.exercise_date: The option is fully vested and exercisable as of the date of the grant. Read SEC document |
| February 25, 2022 Filed Mar 1, 2022 22:11 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $5.90 | $0.00 |
DisclosureSEC source: 0001209191-22-014145 · doc4.xml · derivative · entry 2 Meyers James R · CIK 0001387521 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2032-02-24 F3 · derivative.exercise_date: The option is immediately exercisable in full, but any unvested shares that are purchased under the option are subject to certain repurchase rights by the Issuer upon cessation of the Reporting Person's Continuous Service (as defined in the 2018 EIP). The shares subject to the option will vest in 12 successive equal monthly installments following the grant date, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP. Read SEC document |
| February 25, 2022 Filed Mar 1, 2022 22:11 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | GrantCommon Stock | 12,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-014145 · doc4.xml · nonDerivative · entry 1 Meyers James R · CIK 0001387521 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,700 F1 · shares: Represents shares of common stock issuable upon settlement of a restricted stock unit ("RSU") grant that will fully vest on the first anniversary of the grant date, subject to the Reporting Person's Continuous Service (as defined in the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP")) through such date and subject to acceleration as provided in the 2018 EIP. F2 · balance_after: Includes 1,667 shares subject to the Reporting Person's November 22, 2019 RSU grant that will vest in one final annual installment on November 22, 2022, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through such date and subject to acceleration as provided in the 2018 EIP. Read SEC document |
| June 16, 2021 Filed Jun 17, 2021 22:45 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $7.13 | $0.00 |
DisclosureSEC source: 0001567619-21-012368 · doc1.xml · derivative · entry 1 Meyers James R · CIK 0001387521 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2031-06-15 F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2022 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date. Read SEC document |
| June 03, 2021 Filed Jun 7, 2021 20:25 UTC | Arbutus Biopharma Corp ABUS · Entity 4953 | GrantStock Options · Derivative | 22,000 | $0.00 Strike: $2.95 | $0.00 |
DisclosureSEC source: 0001447028-21-000042 · wf-form4_162309748590209.xml · derivative · entry 1 Meyers James R · CIK 0001387521 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,000 Underlying: Common Stock · 22,000 shares Expires 2031-06-03 F1 · derivative.exercise_price: Reflects the closing price of the Company's common shares on the Nasdaq Stock Market on June 3, 2021, the date of the grant. F2 · derivative.exercise_date: The options are fully vested and exercisable as of the date of the grant. Read SEC document |
| February 25, 2021 Filed Mar 2, 2021 02:01 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | GrantStock Option (Right to Buy) · Derivative | 16,400 | $0.00 Strike: $11.19 | $0.00 |
DisclosureSEC source: 0001209191-21-015508 · doc4.xml · derivative · entry 2 Meyers James R · CIK 0001387521 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,400 Underlying: Common Stock · 16,400 shares Expires 2031-02-24 F3 · derivative.exercise_date: Each option is immediately exercisable for all option shares, but shares purchased under the option are subject to certain repurchase rights by the Issuer upon cessation of the Reporting Person's Continuous Service (as defined in the 2018 EIP, as amended). The shares subject to the option vest in 12 successive equal monthly installments upon the Reporting Person's completion of each month of Continuous Service (as defined in the 2018 EIP, as amended) over the 12-month period measured from the grant date and subject to acceleration as provided in the 2018 EIP, as amended. Read SEC document |
| February 25, 2021 Filed Mar 2, 2021 02:01 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | GrantCommon Stock | 8,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-015508 · doc4.xml · nonDerivative · entry 1 Meyers James R · CIK 0001387521 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,200 F1 · shares: Represents shares of common stock issuable upon settlement of restricted stock units ("RSUs"). The RSUs will fully vest on the first anniversary of the date of grant, subject to the Reporting Person's Continuous Service (as defined in the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP, as amended")), through such date and subject to acceleration as provided in the 2018 EIP, as amended. F2 · balance_after: Includes: (a) 3,333 shares of common stock issuable upon settlement of RSUs granted to the Reporting Person on November 22, 2019 representing two remaining vesting tranches from such RSU grant with such RSUs vesting with respect to 1,666 shares on November 22, 2021 and 1,667 shares on November 22, 2022; and (b) 10,000 shares of common stock issuable upon settlement of RSUs subject to Reporting Person's May 18, 2020 RSU grant that will fully vest on the earlier of (x) May 18, 2021 (the first anniversary of the date of grant) or (y) the day prior to the Issuer's 2021 annual stockholders meeting. The vesting of all such RSUs is subject to the Reporting Person's Continuous Service as defined in the 2018 EIP, as amended, through such dates and subject to acceleration as defined in the 2018 EIP, as amended. Read SEC document |
| June 17, 2020 Filed Jun 19, 2020 16:03 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $8.35 | $0.00 |
DisclosureSEC source: 0001567619-20-012433 · doc1.xml · derivative · entry 1 Meyers James R · CIK 0001387521 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2030-06-16 F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2021 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date. Read SEC document |
| May 28, 2020 Filed Jun 1, 2020 21:04 UTC | Arbutus Biopharma Corp ABUS · Entity 4953 | GrantStock Options · Derivative | 22,000 | $0.00 Strike: $2.16 | $0.00 |
DisclosureSEC source: 0001447028-20-000069 · wf-form4_159104546646108.xml · derivative · entry 1 Meyers James R · CIK 0001387521 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,000 Underlying: Common Stock · 22,000 shares Expires 2030-05-28 F1 · derivative.exercise_price: Reflects the closing price of the Company's common shares on the Nasdaq Stock Market on May 28, 2020, the date of the grant. F2 · derivative.exercise_date: The options are fully vested and exercisable as of the date of the grant. Read SEC document |
| May 18, 2020 Filed May 20, 2020 21:17 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $10.46 | $0.00 |
DisclosureSEC source: 0001209191-20-030956 · doc4.xml · derivative · entry 2 Meyers James R · CIK 0001387521 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2030-05-17 F3 · derivative.exercise_date: Each option is immediately exercisable for all option shares, but shares purchased under the option are subject to certain repurchase rights by the Issuer upon cessation of the Reporting Person's service on the Board of the Directors of the Issuer. The shares subject to the option vest in 12 successive equal monthly installments upon the Reporting Person's completion of each month of Board service over the 12-month period measured from the grant date. Read SEC document |
| May 18, 2020 Filed May 20, 2020 21:17 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | GrantCommon Stock | 2,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-030956 · doc4.xml · nonDerivative · entry 1 Meyers James R · CIK 0001387521 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 F1 · shares: Represents shares of common stock issuable upon settlement of restricted stock units ("RSUs"). The RSUs will fully vest on the earlier of (x) May 18, 2021 (the first anniversary of the date of grant) or (y) the day prior to the 2021 annual stockholders meeting, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such date. F2 · balance_after: Includes 5,000 shares of common stock issuable upon settlement of RSUs granted to the Reporting Person on November 22, 2019. Such RSUs will vest with respect to 1/3rd of the shares in three equal annual installments over the three-year period measured from the date of grant, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such date. Read SEC document |
| May 18, 2020 Filed Jun 3, 2020 20:28 UTC Amendment | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $10.46 | $0.00 |
DisclosureSEC source: 0001209191-20-034020 · doc4a.xml · derivative · entry 2 Meyers James R · CIK 0001387521 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2030-05-17 F4 · derivative.exercise_date: Each option is immediately exercisable for all option shares, but shares purchased under the option are subject to certain repurchase rights by the Issuer upon cessation of the Reporting Person's Continuous Service (as defined in the 2018 EIP, as amended). The shares subject to the option vest in 12 successive equal monthly installments upon the Reporting Person's completion of each month of Continuous Service (as defined in the 2018 EIP, as amended) over the 12-month period measured from the grant date and subject to acceleration as provided in the 2018 EIP, as amended. Read SEC document |
| May 18, 2020 Filed Jun 3, 2020 20:28 UTC Amendment | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | GrantCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-034020 · doc4a.xml · nonDerivative · entry 1 Meyers James R · CIK 0001387521 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 F1 · shares: Represents shares of common stock issuable upon settlement of restricted stock units ("RSUs"). The RSUs will fully vest on the earlier of (x) May 18, 2021 (the first anniversary of the date of grant) or (y) the day prior to the 2021 annual stockholders meeting, subject to the Reporting Person's Continuous Service (as defined in the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP, as amended")), through such date and subject to acceleration as provided in the 2018 EIP, as amended. F2 · shares: This Form 4/A is being filed solely to correct the stated grant amounts which were erroneously reported on Form 4 filed on behalf of the Reporting Person on May 20, 2020. Pursuant to the 2018 EIP, as amended, and the Automatic Grant Program for Non-Employee Directors thereunder, the annual grant amounts increased effective with the approval of the 2018 EIP, as amended, by the stockholders of the Issuer on May 18, 2020. Such previously filed Form 4 incorrectly stated grant amounts pursuant to the Automatic Grant Program for Non-Employee Directors prior to such amendment and restatement of the 2018 Equity Incentive Plan. F3 · balance_after: Includes 5,000 shares of common stock issuable upon settlement of RSUs granted to the Reporting Person on November 22, 2019. Such RSUs will vest with respect to 1/3rd of the shares in three equal annual installments over the three-year period measured from the date of grant, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP, as amended) through such date and subject to acceleration as provided in the 2018 EIP, as amended. Read SEC document |
| November 22, 2019 Filed Nov 26, 2019 21:13 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $9.81 | $0.00 |
DisclosureSEC source: 0001209191-19-058100 · doc4.xml · derivative · entry 2 Meyers James R · CIK 0001387521 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2029-11-21 F2 · derivative.exercise_date: Each option is immediately exercisable for all option shares, but shares purchased under the option are subject to certain repurchase rights by the Issuer upon cessation of the Reporting Person's service on the Board of Directors of the Issuer. The shares subject to the option vest in 36 successive equal monthly installments upon the Reporting Person's completion of each month of Board service over the 36-month period measured from the grant date. Read SEC document |
| November 22, 2019 Filed Nov 26, 2019 21:13 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | GrantCommon Stock | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-058100 · doc4.xml · nonDerivative · entry 1 Meyers James R · CIK 0001387521 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 F1 · shares: Represents shares of common stock issuable upon settlement of restricted stock units ("RSUs"). The RSUs will vest with respect to 1/3rd of the shares in three equal annual installments over the three-year period measured from the date of grant, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such date. Read SEC document |
| August 17, 2019 Filed Aug 20, 2019 20:16 UTC | Arbutus Biopharma Corp ABUS · Entity 4953 | GrantStock Options · Derivative | 22,000 | $0.00 Strike: $1.50 | $0.00 |
DisclosureSEC source: 0001447028-19-000053 · wf-form4_156633218636070.xml · derivative · entry 1 Meyers James R · CIK 0001387521 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,000 Underlying: Common Stock · 22,000 shares Expires 2029-08-17 F1 · derivative.exercise_price: Reflects the closing price of the Company's common shares on the Nasdaq Stock Market on August 16, 2019, the trading day immediately preceding the date of the grant. Read SEC document |
| June 19, 2019 Filed Jun 21, 2019 18:01 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | GrantStock Option (Right to Buy) · Derivative | 14,000 | $0.00 Strike: $11.31 | $0.00 |
DisclosureSEC source: 0001567619-19-013822 · doc1.xml · derivative · entry 1 Meyers James R · CIK 0001387521 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,000 Underlying: Common Stock · 14,000 shares Expires 2029-06-18 F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2020 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date. Read SEC document |
| December 20, 2018 Filed Dec 27, 2018 17:42 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | GrantStock Option (right to buy) · Derivative | 28,000 | $0.00 Strike: $14.04 | $0.00 |
DisclosureSEC source: 0001567619-18-008731 · doc1.xml · derivative · entry 1 Meyers James R · CIK 0001387521 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,000 Underlying: Common Stock · 28,000 shares Expires 2028-12-19 F1 · derivative.exercise_date: 1/36th of the shares subject to the option vest on each monthly anniversary measured from December 20, 2018 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the third anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each such date. Read SEC document |
| October 18, 2018 Filed Oct 22, 2018 17:31 UTC | Arbutus Biopharma Corp ABUS · Entity 4953 | GrantDirector Share Option (Right to Buy) · Derivative | 44,000 | $0.00 Strike: $4.71 | $0.00 |
DisclosureSEC source: 0001567619-18-004376 · doc1.xml · derivative · entry 1 Meyers James R · CIK 0001387521 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,000 Underlying: Common Shares · 44,000 shares Expires 2028-10-18 F1 · derivative.exercise_date: The options vest as follows: 1/3 on 10/18/2019; 1/3 on 10/18/2020; and 1/3 on 10/18/2021. Read SEC document |
| February 21, 2018 Filed Feb 23, 2018 23:41 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GiftCommon Stock | 2,323 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-008130 · form4.xml · nonDerivative · entry 6 Meyers James R · CIK 0001387521 · EVP Worldwide Commercial Ops 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 132,083 F4 · shares: Shares gifted to family trust. Read SEC document |
| February 21, 2018 Filed Feb 23, 2018 23:41 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GiftCommon Stock | 2,323 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-008130 · form4.xml · nonDerivative · entry 5 Meyers James R · CIK 0001387521 · EVP Worldwide Commercial Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,393 F4 · shares: Shares gifted to family trust. Read SEC document |
| February 21, 2018 Filed Feb 23, 2018 23:41 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Tax withholdingCommon Stock | 1,647 | $80.69 | $132,896.43 |
DisclosureSEC source: 0001127602-18-008130 · form4.xml · nonDerivative · entry 4 Meyers James R · CIK 0001387521 · EVP Worldwide Commercial Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,716 Read SEC document |
| February 21, 2018 Filed Feb 23, 2018 23:41 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantCommon Stock | 1,581 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-008130 · form4.xml · nonDerivative · entry 3 Meyers James R · CIK 0001387521 · EVP Worldwide Commercial Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,363 F3 · shares: Represents shares of the Issuer's common stock subject to specific tranches of the performance share award made to the Reporting Person on February 1, 2015. Such tranches of shares were subject to performance-vesting and service-vesting requirements and became issuable on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of the Issuer's Board of Directors. Read SEC document |
| February 21, 2018 Filed Feb 23, 2018 23:41 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantCommon Stock | 4,846 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-008130 · form4.xml · nonDerivative · entry 2 Meyers James R · CIK 0001387521 · EVP Worldwide Commercial Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,782 F2 · shares: Represents shares of the Issuer's common stock subject to specific tranches of the performance share awards made to the Reporting Person on February 1, 2016, and February 2, 2017. Such tranches of shares were subject to both performance-vesting and service-vesting requirements. The performance vesting requirement was satisfied on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of the Issuer's Board of Directors. However, the shares will not be issued to the Reporting Person until such individual satisfies the applicable service-vesting requirements by continuing in the Issuer's employ through December 31, 2018 and December 31, 2019, respectively. Read SEC document |
| February 15, 2018 Filed Feb 23, 2018 23:41 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantCommon Stock | 221 | $62.35 | $13,778.80 |
DisclosureSEC source: 0001127602-18-008130 · form4.xml · nonDerivative · entry 1 Meyers James R · CIK 0001387521 · EVP Worldwide Commercial Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,936 F1 · shares: Shares were acquired under the Gilead Sciences, Inc. Employee Stock Purchase Plan. Read SEC document |
| February 01, 2018 Filed Feb 6, 2018 01:51 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantNon-qualified Stock Option (Right to Buy) · Derivative | 75,490 | $0.00 Strike: $83.49 | $0.00 |
DisclosureSEC source: 0001127602-18-004158 · form4.xml · derivative · entry 1 Meyers James R · CIK 0001387521 · EVP Worldwide Commercial Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,490 Underlying: Common Stock · 75,490 shares Expires 2028-02-01 F1 · derivative.exercise_date: The options have a four year vesting schedule. 25% of the options will vest on the first anniversary date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| January 16, 2018 Filed Jan 18, 2018 23:31 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $21.58 | $0.00 |
DisclosureSEC source: 0001127602-18-002122 · form4.xml · derivative · entry 4 Meyers James R · CIK 0001387521 · EVP Worldwide Commercial Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 100,000 shares Expires 2018-01-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: The options have a five year vesting schedule. 20% vest on the first anniversary of the date of grant. The balance will vest 5% quarterly thereafter until fully vested. Read SEC document |
| January 16, 2018 Filed Jan 18, 2018 23:31 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 24,843 | $80.99 | $2,012,096.68 |
DisclosureSEC source: 0001127602-18-002122 · form4.xml · nonDerivative · entry 3 Meyers James R · CIK 0001387521 · EVP Worldwide Commercial Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,715 F4 · price: Sale prices reported for the transactions reported here range from $80.57 to $81.55. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| January 16, 2018 Filed Jan 18, 2018 23:31 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 75,157 | $80.00 | $6,012,266.89 |
DisclosureSEC source: 0001127602-18-002122 · form4.xml · nonDerivative · entry 2 Meyers James R · CIK 0001387521 · EVP Worldwide Commercial Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,558 F3 · price: Sale prices reported for the transactions reported here range from $79.56 to $80.56. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| January 16, 2018 Filed Jan 18, 2018 23:31 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 100,000 | $21.58 | $2,157,500.00 |
DisclosureSEC source: 0001127602-18-002122 · form4.xml · nonDerivative · entry 1 Meyers James R · CIK 0001387521 · EVP Worldwide Commercial Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,715 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| November 09, 2017 Filed Nov 14, 2017 00:57 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GiftCommon Stock | 1,327 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-031967 · form4.xml · nonDerivative · entry 4 Meyers James R · CIK 0001387521 · EVP Worldwide Commercial Ops 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 129,760 Read SEC document |
| November 09, 2017 Filed Nov 14, 2017 00:57 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GiftCommon Stock | 1,327 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-031967 · form4.xml · nonDerivative · entry 3 Meyers James R · CIK 0001387521 · EVP Worldwide Commercial Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,715 Read SEC document |
| November 09, 2017 Filed Nov 14, 2017 00:57 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Tax withholdingCommon Stock | 1,373 | $73.02 | $100,256.46 |
DisclosureSEC source: 0001127602-17-031967 · form4.xml · nonDerivative · entry 2 Meyers James R · CIK 0001387521 · EVP Worldwide Commercial Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,042 Read SEC document |
| November 09, 2017 Filed Nov 14, 2017 00:57 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantCommon Stock | 2,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-031967 · form4.xml · nonDerivative · entry 1 Meyers James R · CIK 0001387521 · EVP Worldwide Commercial Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,415 F1 · shares: Issuance of common stock upon vesting of certain performance share awards on November 9, 2017. Read SEC document |
| November 05, 2017 Filed Nov 7, 2017 22:47 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionRestricted Stock Unit · Derivative | 4,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-031522 · form4.xml · derivative · entry 5 Meyers James R · CIK 0001387521 · EVP Worldwide Commercial Ops 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,460 Underlying: Common Stock · 4,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · derivative.exercise_date: The restricted stock units have a four year vesting schedule. 25% vest on the anniversary of the date of grant until fully vested. F1 · derivative.expiration_date: The restricted stock units have a four year vesting schedule. 25% vest on the anniversary of the date of grant until fully vested. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.